Market Overview
Global Fupentixol Hydrochloride market size was valued at USD 1560 million in 2024 and is projected to reach USD 3367 million by 2031, exhibiting a CAGR of 11.9% during the forecast period.
Fupentixol Hydrochloride is a thioxanthene derivative antipsychotic medication primarily used to treat schizophrenia, depression, and melancholic neurosis. As a dopamine receptor antagonist, it helps regulate neurotransmitter activity in the brain. The drug is available in multiple dosages including 0.5mg, 1mg, and 5mg formulations to accommodate different treatment regimens.
USD 1560 million in 2024
3367 million by 2031
of 11.9%
1Mg Segment Dominates the Market Due to its Balanced Efficacy and Common Prescription in Initial Treatment Phases
The market is segmented based on type into different dosage strengths, which cater to varying patient needs in antipsychotic therapy. These dosages allow for flexible administration tailored to the severity of symptoms and patient response.
0.5Mg 1Mg 5Mg
By Application
The market is segmented based on application into key therapeutic areas where Fupentixol Hydrochloride demonstrates proven efficacy in managing psychiatric conditions. Schizophrenia Depression Melancholic Neurosis
Portable Neuromonitoring Device Market
Our Key Players
Lundbeck (Denmark)
Haisco Pharma (China)
Centaur Pharma (India)
Renan Pharmaceutical (China)
GC (South Korea)
Shenghuaxi (China)
https://www.24lifesciences.com
